Lizhu Medicine "recombination of whole human source anti-OX40 monoclonal antibody injection" clinical trial application accepted by the State Drug Administration
-
Last Update: 2020-06-10
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
recently, thePharmaceutical(http://announced that its holding affiliatedcompany(http://Zhuhai Lizhu single anti-biotechnology Co., Ltddeclared "recombination of all-human source anti-OX40 monoclonal antibody injection" clinicaltest(http://application was accepted by the State Drug AdministrationIt is understood that "recombination of whole human source anti-OX40 monoclonal antibody injection" after 2 years of research and development, clinical trial application signed on March 12, 2019 (acceptance number: CXSL1900024 country)as of the date of the announcement, thehas invested approximately RMB 16.9695 million in research and development investment of RMB16.9695 million in "recombined whole-person anti-OX40 monoclonal antibody injection"so far, including Lizhu mono-resistance, the domestic "OX40" as the target of the single anti-
drug(http:// only 2 clinical applications, one of which has been approved clinical Lizhu Pharmaceuticals said that the application for clinical trials of this product has been accepted, pending approval of clinical trials, still must be in accordance with the relevant content of the approval of clinical research and GMP certification and approval by the FDA before listing
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
